NCCN Framework for Resource Stratification of NCCN Guidelines Now Available
NCCN has published the NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework) for Cervical Cancer.
The NCCN Framework accounts for variability in available clinical treatment resources. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are used widely around the world, including in several regions with low- to mid-level resources. The goal of the NCCN Framework is to identify appropriate treatment at 4 resource levels—Basic, Limited, Enhanced, and Maximal—and deliver a tool for health care providers to identify treatment options that will provide the best possible outcomes at a given resource level. The NCCN Framework outlines a rational approach for transition between resource levels when building a health system, with the goal of providing the highest attainable level of care.
The 4 levels of NCCN Framework resources include:
Basic: Essential services needed to provide basic minimal standard of care
Limited: Services that provide major improvements in disease outcomes (eg, survival) that are not cost-prohibitive
Enhanced: Services that provide lesser improvements in disease outcomes, or services that provide major improvements in disease outcomes but are cost-prohibitive at lower resource levels
Maximal: Services that do not provide improvement in disease outcomes but are desirable services, or services that provide minor improvements in disease outcomes but are cost-prohibitive in lower resource levels
NCCN develops and maintains 61 NCCN Guidelines for cancer prevention, detection, treatment, and supportive care, as well as more than 70 translations of NCCN content in 12 languages and several international adaptations that allow for consideration of biologic differences in populations, local accessibility, and regulatory status of interventions used in specific global regions.
The NCCN Framework for Breast and Hepatobiliary Cancers will be published later this year. A preliminary version of the NCCN Framework for Cervical Cancer was released in March 2015.
NCCN Seeking Poster Presentations From Nation's Top Oncology Researchers
NCCN is now accepting original abstracts for consideration for presentation during the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care General Poster Session, March 31–April 1, 2016, at The Diplomat, in Hollywood, Florida.
NCCN welcomes original abstracts from investigators in the general oncology community; submissions will be accepted from NCCN Member Institutions, academic institutions, teaching and community hospitals, and industry.
Topics may fall into the general areas below:
Clinical oncology (all phases)
Best practices in implementation and use of clinical practice guidelines
Outcomes and health services research
Bioinformatics/Information technology sciences
The NCCN General Poster Session, including submission review, is overseen by the NCCN Oncology Research Program (ORP). The submission deadline for the NCCN General Poster Session Call for Abstracts is Friday, November 6, 2015, at 11:59 PM ET. First authors can expect to receive notification via e-mail in mid-December 2015.
Abstracts will be evaluated using a peer-review process. Oncology research faculty from NCCN Member Institutions will serve as peer reviewers and approve research to display at the general poster session. All approved original abstracts will be published on JNCCN.org. Select abstracts will also be published in print in JNCCN.
The NCCN Annual Conference: Advancing the Standard of Cancer Care attracts more than 1500 attendees from across the United States and the globe, including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of people with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Guidelines, the data upon which the NCCN Guidelines are based, and quality initiatives in oncology.
To learn more about the NCCN 21st Annual Conference or the NCCN General Poster Session, visit NCCN.org/AC2016.
Updated NCCN Guidelines for Patients and New NCCN Quick Guide for Multiple Myeloma Now Available
NCCN has published an updated NCCN Guidelines for Patients: Multiple Myeloma as well as the first NCCN Quick Guide for Multiple Myeloma. This NCCN Patient Guideline has been updated from Version 1.2014 to Version 1.2015 to reflect the most recent updates in the NCCN Guidelines for Multiple Myeloma.
The NCCN Guidelines for Patients: Multiple Myeloma, Version 1.2015, includes important changes to recommended systemic therapy options and combinations in the treatment guide. Two new combination regimens have been added as options for additional treatment for relapse or progressive disease. One new option is the combination of carfilzomib, lenalidomide, and dexamethasone. The second new option is the combination of panobinostat, bortezomib, and dexamethasone. Panobinostat is the newest drug to be approved by the FDA for the treatment of multiple myeloma. It is indicated for patients who have received at least two prior treatments, including bortezomib (Velcade) and an immunotherapy drug.
The NCCN Quick Guide for Multiple Myeloma summarizes key points of the NCCN Guidelines for Patients: Multiple Myeloma, Version 1.2015. Key points include myeloma assessment for treatment planning and recommended options for initial and subsequent treatment.
The NCCN Guidelines for Patients and NCCN Quick Guide for Multiple Myeloma provide the same current and accurate cancer information on health care options that clinicians access in the NCCN Guidelines. Digital versions of these patient resources are available to view and download free-of-charge on NCCN.org/patients.
NCCN currently offers NCCN Guidelines for Patients for the following: Breast Cancer: Stages 0–IV; Colon, Esophageal, Non–Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphoblastic Leukemia; Caring for Adolescents and Young Adults; Chronic Myelogenous Leukemia; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; and Soft Tissue Sarcoma. NCCN Quick Guide sheets are currently available for Esophageal Cancer, Prostate Cancer, Stage IV Breast Cancer, Lung Cancer Screening, and Multiple Myeloma.
NCCN is committed to developing a comprehensive patient library with support from the NCCN Foundation.
If the inline PDF is not rendering correctly, you can download the PDF file here.